订阅小程序
旧版功能

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.

Sumanta K. Pal,Javier Puente,Daniel Y. C. Heng,Hilary Glen,Piotr Koralewski,Daniil Stroyakovskiy,Boris Alekseev,Francis Parnis,Daniel Castellano,Tudor Ciuleanu,Jae Lyun Lee,Kaisa Sunela, Karen O'Hara,Terri A. Binder,Lixian Peng,Alan D. Smith,Sun Young Rha

European Urology（2022）

引用 20|浏览19
关键词
Efficacy,Lenvatinib plus everolimus,Phase 2 trial,Renal cell carcinoma,Safety,Starting dose
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要